Advanced Solid Tumors: MK-1084 Treatment

We are testing a new drug, MK-1084, for patients with advanced solid tumors that have a KRAS mutation. This study aims to understand its safety and how it may help in treating these tumors.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Odense University Hospital
Department of Oncology
Odense, Denmark
Humanitas Research Hospital
U.O di Oncologia ed Ematologia
Rozzano, Italy
Azienda Ospedaliera Universitaria Senese
U.O.C. Immunoterapia Oncologica
Siena, Italy

Sponsor: Merck Sharp & Dohme LLC
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.